Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Lymphoma 2Leukemia, Hairy Cell 2Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Carcinoma in Situ 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 48Filgrastim 21fludarabine phosphate 19Rituximab 19Etoposide 19Peripheral Blood Stem Cell Transplantation 17fludarabine 16Prednisone 16Vincristine 15Cytarabine 12Doxorubicin 11blinatumomab 8Methotrexate 8Dexamethasone 8Cyclosporine 8Bortezomib 8venetoclax 7Vorinostat 7Paclitaxel 7Melphalan 7Lenalidomide 7Calcium Dobesilate 7Biopsy 7Specimen Handling 6Radiotherapy 6Indium 6tanespimycin 5aldesleukin 5Tacrolimus 5Inotuzumab Ozogamicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Burkitt Lymphoma × Diphenhydramine × Clear all
NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡